Mylan claims win in Lantus patent battle, but legal war with Sanofi is far from over
Earlier this week, the FDA took aim at escalating insulin prices that have forced diabetics to ration out the drug as out-of-pocket costs soar. Now, the US Patent and Trademark Office has denied Sanofi’s claim on two patents for its top-selling Lantus, in response to a petition from Mylan, although ongoing litigation between the two companies in US courts could still subvert a potential launch of the generic drugmaker’s copycat version.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.